<qa>  What is the name of the trial that was conducted for patients with refractory multiple myAn open-label, single-arm, multi-centre phase II trial for patients with refractory multiple myeloma and with BRAFV600EK Mutation to evaluate the efficacy of the kinase inhibitors Encorafenib LGX818 in combination with Binimetinib MEK162. The patients must have received at least two prior therapy regimen at least one immunomodulatory drug and one proteasome inhibitor. 